Effect Of Calcitriol On Neutrophil To Lymphocytes Ratio And High Sensitivity C-Reactive Protein Covid-19 Patients

Universitas Sebelas Maret16 enrolled

Overview

This research is a study that compares the administration of calcitriol with the outcomes of COVID-19 patients

This research was an observational analytic cohort retrospective study in which the subjects were moderate degree COVID-19 inpatients in Sebelas Maret University Hospital divided into two groups. The control group received standard therapy, while the treatment group received calcitriol 2x400 iu per day.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

QUADRUPLE

Enrollment

Conditions

COVID-19

Interventions

CalcitriolDRUG

The treatment group received calcitriol 2x400 iu per day for five days. Calcitriol uses Oscal, obtained from Kalbe Pharma

PlaceboOTHER

Placebo give 2x1 per day for five day

Eligibility

Sex: ALLMin age: 18 YearsMax age: 60 Years

Medical Language ↔ Plain English

Inclusion Criteria: * COVID-19 patients, hospitalized patients, and patients aged 18-60 years Exclusion Criteria: * pregnancy

Locations (1)

Universitas Sebelas Maret Hospital

Sukoharjo, Central Java, Indonesia

Outcomes

Primary Outcomes

HsCRP

High-sensitivity C-reactive protein (hsCRP) is a marker of inflammation

Time frame: Hs CRP (high sensitive c reactive protein) examination was carried out on the first day of hospitalization and the 5th day of hospitalization

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.